Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...